Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Novartis
University Hospital, Limoges
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
Quetzal Therapeutics
Orca Biosystems, Inc.
Taiho Oncology, Inc.
Celgene
University of Southern California
Assistance Publique - Hôpitaux de Paris
Cellectar Biosciences, Inc.
Center for International Blood and Marrow Transplant Research
Takeda
Eli Lilly and Company
Massachusetts General Hospital
H. Lee Moffitt Cancer Center and Research Institute
Ossium Health, Inc.
Memorial Sloan Kettering Cancer Center
Center for International Blood and Marrow Transplant Research
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eli Lilly and Company
Medical College of Wisconsin
University of Michigan Rogel Cancer Center